Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group.

BACKGROUND The frequency of, course of, and factors associated with cardiovascular abnormalities in pediatric HIV are incompletely understood. METHODS AND RESULTS A baseline echocardiogram (median age, 2.1 years) and 2 years of follow-up every 4 months were obtained as part of a prospective study on 196 vertically HIV-infected children. Age- or body surface area-adjusted z scores were calculated by use of data from normal control subjects. Although 88% had symptomatic HIV infection, only 2 had CHF at enrollment, with a 2-year cumulative incidence of 4.7% (95% CI, 1.5% to 7.9%). All mean cardiac measurements were abnormal at baseline (decreased left ventricular fractional shortening [LV FS] and contractility and increased heart rate and LV dimension, mass, and wall stresses). Most of the abnormal baseline cardiac measurements correlated with depressed CD4 cell count z scores and the presence of HIV encephalopathy. Heart rate and LV mass showed significantly progressive abnormalities, whereas FS and contractility tended to decline. No association was seen between longitudinal changes in FS and CD4 cell count z score. Children who developed encephalopathy during follow-up had depressed initial FS, and FS continued to decline during follow-up. CONCLUSIONS Subclinical cardiac abnormalities in HIV-infected children are common, persistent, and often progressive. Dilated cardiomyopathy (depressed contractility and dilatation) and inappropriate LV hypertrophy (elevated LV mass in the setting of decreased height and weight) were noted. Depressed LV function correlated with immune dysfunction at baseline but not longitudinally, suggesting that the CD4 cell count may not be a useful surrogate marker of HIV-associated LV dysfunction. However, the development of encephalopathy may signal a decline in FS.

[1]  A. Garson,et al.  The Science and Practice of Pediatric Cardiology , 1998 .

[2]  S. Colan,et al.  Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus. , 1997, The American journal of clinical nutrition.

[3]  David A. Schoenfeld,et al.  A Random-Effects Model for Multiple Characteristics with Possibly Missing Data , 1997 .

[4]  Robert H. Cleveland,et al.  The pediatric pulmonary and cardiovascular complications of vertically transmitted human immunodeficiency virus (P2C2 HIV) infection study: design and methods. The P2C2 HIV Study Group. , 1996, Journal of clinical epidemiology.

[5]  G. Scarlatti.  Paediatric HIV infection , 1996, The Lancet.

[6]  I. Hanson,et al.  ENCEPHALOPATHY IN CHILDREN WITH PERINATALLY ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS INFECTION , 1996, Pediatrics.

[7]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[8]  H. Barnhart,et al.  Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. , 1996, Pediatrics.

[9]  M. Yacoub,et al.  Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy , 1996, The Lancet.

[10]  B. Biondi,et al.  A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. , 1996, The New England journal of medicine.

[11]  G. Raab,et al.  CD4 and CD8 lymphocytes in diagnosis and disease progression of pediatric HIV infection. , 1996, Pediatric AIDS and HIV infection.

[12]  S. Colan,et al.  Immunoglobulins and left ventricular structure and function in pediatric HIV infection. , 1995, Circulation.

[13]  M. Domanski,et al.  Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. , 1995, The Journal of pediatrics.

[14]  M. Newell,et al.  HIV infection in children: a guide to practical management. , 1995 .

[15]  C. Giaquinto,et al.  Features of children perinatally infected with HIV‐1 surviving longer than 5 years , 1994 .

[16]  Ann Marie Swart,et al.  Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection , 1994, The Lancet.

[17]  C. Giaquinto,et al.  Features of children perinatally infected with HIV-1 surviving longer than 5 years Italian Register for HIV Infection in Children , 1994, The Lancet.

[18]  J. Moye,et al.  Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. , 1993, Journal of acquired immune deficiency syndromes.

[19]  E. Orav,et al.  Cardiac morbidity and related mortality in children with HIV infection. , 1993, JAMA.

[20]  Robert Schooley,et al.  CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine , 1993, Annals of Internal Medicine.

[21]  L. Markson,et al.  Survival experience of 789 children with the acquired immunodeficiency syndrome. , 1993, The Pediatric infectious disease journal.

[22]  S. Colan,et al.  Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. , 1992, The New England journal of medicine.

[23]  A. Plebani,et al.  Prognostic factors and survival in children with perinatal HIV-1 infection , 1992, The Lancet.

[24]  S. Colan,et al.  Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. , 1992, Journal of the American College of Cardiology.

[25]  E. Abrams,et al.  Paediatric HIV infection. , 1991, Bailliere's Clinical Haematology.

[26]  S. Colan,et al.  Identification of human immunodeficiency virus-1 RNA and DNA in the heart of a child with cardiovascular abnormalities and congenital acquired immune deficiency syndrome. , 1990, The American journal of cardiology.

[27]  M. Roberts,et al.  Autonomic function and human immunodeficiency virus infection , 1990, Neurology.

[28]  S. Colan,et al.  Cardiovascular manifestations of human immunodeficiency virus infection in infants and children. , 1989, The American journal of cardiology.

[29]  R. Virmani,et al.  Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. , 1988, Journal of the American College of Cardiology.

[30]  Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. , 1987, MMWR. Morbidity and mortality weekly report.

[31]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.

[32]  Bethany J Figg,et al.  National Institute of Child Health and Human Development , 2013 .

[33]  H. Burchell,et al.  Focal myocarditis associated with pheochromocytoma. , 1966, The New England journal of medicine.